MarketBeat
21 Nov 2026, 09:12 UTC · 1h ago
NeoGenomics Touts 29% Sequencing Growth, Plans Sales Push for Cancer Tests
Impact · against what's priced in
NeoGenomics provides positive catalysts via potential coverage expansions for RaDaR ST and planned 2027 margin expansion, though these are tempered by a conservative 2027 revenue growth base case. The immediate financial beat and guidance raise are likely already reflected in the current price.
- NEO+0.50
No priced-in read yet
- In context
The potential to double the RaDaR addressable market share from 20% to 40% of a $20B TAM through pending coverage decisions and the expectation of gross margin expansion in 2027 provide tangible forward catalysts.
Read from the article alone





